About Cage Pharma

About company

Cage Pharma is a pre-clinical biopharmaceutical company that develops new drugs targeting the metabolism of tumors. The company's encapsulated anti-cancer agent is developed using a novel formulation of a particular halopyruvate called 3-bromopyruvate to target cancer by directly attacking one of its key hallmarks, tumor glycolysis, enabling medical practitioners to achieve efficacy as an anti-cancer agent with a controlled and mild toxicity profile. Cage Pharma was founded in 2017 and is headquartered in Baltimore, Maryland.